MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • MDS Virtual Congress 2021

    Predictive factors of LCIG infusion therapy adherence – a single-center study of 103 consecutive LCIG patients

    V. Viljaharju, T. Mertsalmi, KAM. Pauls, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)

    Objective: The objectives of this study were to find predictive factors for early dropout from levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD)…
  • MDS Virtual Congress 2021

    Effects of freezing gait and medication on postural control during prolonged standing in individuals with Parkinson’s disease

    L. Cupertino, CR. de Souza, CN. de Oliveira, R. Treza, SM. Hondo, E. Los Angeles, C. Bernardo, MJ. Carvalho, DB. Coelho (Sp, Brazil)

    Objective: To analyze the effects of freezing of gait (FoG) and medication on postural adjustments during prolonged standing in individuals with Parkinson's disease (PD). Background:…
  • MDS Virtual Congress 2021

    CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson’s disease with the OLAR® platform

    E. Berkovich (Petch-Tikva, Israel)

    Objective: Development of a treatment for nocturnal and early morning OFF symptomology in Parkinson’s disease. Background: Levodopa Parkinson’s disease (PD) treatment is limited by its…
  • MDS Virtual Congress 2021

    Levodopa responsive gait dynamics in ON- and OFF-state freezing of gait in Parkinson’s disease

    T. Virmani, L. Pillai, A. Glover, R. Landes (Little Rock, USA)

    Objective: To determine which spatiotemporal gait parameters respond to levodopa in Parkinson’s patients with levodopa ON- and OFF-state gait freezing. Background: Levodopa-ON-state gait freezing is…
  • MDS Virtual Congress 2021

    Deep brain stimulation in Parkinson’s disease

    S. Laassila, N. Chtaou (Fez, Morocco)

    Objective: Study the various clinical, electrophysiological and therapeutic parameters of operated patients. Evaluate the effectiveness of deep brain stimulation of STN in Parkinson's disease. Background:…
  • MDS Virtual Congress 2021

    Validation of a real- time monitoring system to detect motor symptoms in patients with Parkinson´s disease treated with Levodopa Carbidopa Intestinal Gel

    A. Bougea, M. Palkopoulou, S. Pantinaki, A. Antonoglou, E. Efthymiopoulou (Athens, Greece)

    Objective: Our aim was to analyze the ability of system to combine information on OFF periods, falls and dyskinesias of patients with PD. Background: Levodopa…
  • MDS Virtual Congress 2021

    A retrospective review of clinical and MRI/CT radiological correlation in progressive supranuclear palsy (PSP)

    T. Wongwarawipat, G. Shepherd, A. Chatterjee (Reading, United Kingdom)

    Objective: To investigate the clinical and MRI/CT radiological correlation to improve the diagnosis and management of PSP Background: PSP is a rare progressive neurodegenerative disease…
  • MDS Virtual Congress 2021

    Effect of dopaminergic treatment on digital sensor features in Phase II PASADENA Part 1 in early Parkinson’s disease

    B. van Lier, J. Anzures Cabrera, E. Volkova-Volkmar, L. Essioux, H. Svoboda, W. Zago, G. Pagano, R. Postuma, M. Lindemann, K. Taylor, F. Lipsmeier (Basel, Switzerland)

    Objective: To characterize the sensitivity of smartphone and -watch sensor features to levodopa and dopamine agonist (DA-Tx) treatment. Background: Digital health technology tools (DHTTs) enable…
  • MDS Virtual Congress 2021

    Comparison of Antiparkinsonian Medication Initiation and Levodopa-Equivalent Daily Dose Across PPMI, STEADY-PD III, and SURE-PD3

    J. Chan, N. Hanan, J. Lowell, M. Kostrzebski, D. Penz, C. Tarolli, T. Mestre, A. Lutz, C. Lungu, C. Coffey, D. Oakes, M. Schwarzschild, T. Simuni, E. Macklin (Boston, USA)

    Objective: To compare use of antiparkinsonian medications (APM) among early Parkinson disease (PD) patients across clinical study cohorts. Background: Initiation of APM is a key…
  • MDS Virtual Congress 2021

    Time to diagnosis of clinically established Parkinson’s disease or atypical parkinsonism: is a 5-year follow-up period necessary?

    M. Rossi, S. Perez-Lloret, M. Merello (Buenos Aires, Argentina)

    Objective: To determine the time frame to the diagnosis of clinically established Parkinson’s disease (PD) or atypical parkinsonism after an acute levodopa challenge (LDC) for…
  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley